Application
Western blot analysis of FOXD1 expression in SP2/0 whole cell lysate.WB
C, D. qRT-PCR and western blot assay indicating that FOXD1-AS1 knockdown decreases the expression level of FOXD1, whereas FOXD1-AS1 overexpression increases the expression level of FOXD1.G. RNA pull-down assay suggesting that FOXD1 binds with FOXD1-AS1.WB
(J) FOXD1 knockdown induces the protein level of LDHA, PKM, and ENO1, while FOXD1 overexpression increases the expression level of these genes in CNE-1.WB
(A) Knockdown of FOXD1-AS1 could decrease the protein level of FOXD1, LDHA, PKM, and ENO1, and overexpression of FOXD1 significantly reverses the effects of FOXD1-AS1 silencing in CNE-1 and 5-8F cells.WB
A. Western blotting analysis of FOXD1, LDHA, PKM, and ENO1 expression in 10 pairs of tumor tissues and normal tissues from patients with NPC. B. Immunohistochemical detection of FOXD1 protein expression in tumor tissues and normal tissues of patients with NPC.D. Immunohistochemical assay indicating that the silencing of FOXD1-AS1 decreases FOXD1, Ki67, and caspase3 protein levels in tumor tissues of mice, whereas FOXD1 overexpression reverses the protein levels of these genes.WB
E. Western blotting assay was performed to detect the expression level of FOXD1 and glycolysis-related proteins in the tumor tissues of mice.WB
C, D. qRT-PCR and western blot assay indicating that FOXD1-AS1 knockdown decreases the expression level of FOXD1, whereas FOXD1-AS1 overexpression increases the expression level of FOXD1.G. RNA pull-down assay suggesting that FOXD1 binds with FOXD1-AS1.WB
(J) FOXD1 knockdown induces the protein level of LDHA, PKM, and ENO1, while FOXD1 overexpression increases the expression level of these genes in CNE-1 and 5-8F cells.| Product Name | FOXD1 Antibody (F-21) |
|---|---|
| Antibody Type | Primary Antibodies |
| Modification Notes | The FOX family of transcription factors share a common DIUA binding domain termed a winged-helix or forkhead domain. Many FOX proteins play important roles in development, metabolism, cancer and aging. FOXD1 (also designated brain factor 2 or BF-2) is involved in regulating inflammation as well as kidney and retinal development. FOXD1 regulates the activity of NFAT and NF˚B. Deficiency of FOXD1 results in multiorgan systemic inflammation, exaggerated Th cell-derived cytokine production, and T cell proliferation in autogolgous MLRs. In kidneys, FOXD1 controls the production of signals required for the normal transition of induced mesenchyme into tubular epithelium and full growth and branching of the collecting system. Deletion of FOXD1 results in renal abnormalities. FOXD2 acts as a modulator of T cell activation. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | ELISAIPWB |
| WB:1:500~1:2000 IP:1:100~1:500 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Alternative Names | recommended for detection of FOXD1 of mouse origin by WB IP and ELISA |
|---|---|
| Tissue Specificity | recommended for detection of FOXD1 of mouse origin by WB, IP and ELISA |
| Entrez Gene | 15229 |
|---|
Application
Western blot analysis of FOXD1 expression in SP2/0 whole cell lysate.
WB
C, D. qRT-PCR and western blot assay indicating that FOXD1-AS1 knockdown decreases the expression level of FOXD1, whereas FOXD1-AS1 overexpression increases the expression level of FOXD1.G. RNA pull-down assay suggesting that FOXD1 binds with FOXD1-AS1.
WB
(J) FOXD1 knockdown induces the protein level of LDHA, PKM, and ENO1, while FOXD1 overexpression increases the expression level of these genes in CNE-1.
WB
(A) Knockdown of FOXD1-AS1 could decrease the protein level of FOXD1, LDHA, PKM, and ENO1, and overexpression of FOXD1 significantly reverses the effects of FOXD1-AS1 silencing in CNE-1 and 5-8F cells.
WB
A. Western blotting analysis of FOXD1, LDHA, PKM, and ENO1 expression in 10 pairs of tumor tissues and normal tissues from patients with NPC. B. Immunohistochemical detection of FOXD1 protein expression in tumor tissues and normal tissues of patients with NPC.D. Immunohistochemical assay indicating that the silencing of FOXD1-AS1 decreases FOXD1, Ki67, and caspase3 protein levels in tumor tissues of mice, whereas FOXD1 overexpression reverses the protein levels of these genes.
WB
E. Western blotting assay was performed to detect the expression level of FOXD1 and glycolysis-related proteins in the tumor tissues of mice.
WB
C, D. qRT-PCR and western blot assay indicating that FOXD1-AS1 knockdown decreases the expression level of FOXD1, whereas FOXD1-AS1 overexpression increases the expression level of FOXD1.G. RNA pull-down assay suggesting that FOXD1 binds with FOXD1-AS1.
WB
(J) FOXD1 knockdown induces the protein level of LDHA, PKM, and ENO1, while FOXD1 overexpression increases the expression level of these genes in CNE-1 and 5-8F cells.| Application Notes | WB:1:500~1:2000 IP:1:100~1:500 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
